PTC Therapeutics Inc

Most Recent

  • uploads///dECLINES
    Company & Industry Overviews

    S&P 500’s Top Losses: Why Biogen Declined

    Biogen, which is an American multinational biotechnology company, was the S&P 500’s top loss on June 18.

    By Val Kensington
  • uploads///Exon skipping
    Earnings Report

    BioMarin Has Suffered from Kyndrisa’s Rejection

    The recent fall in BioMarin’s stock price is due to the rejection of its drug Kyndrisa, indicated for Duchenne muscular dystrophy.

    By Jillian Dabney
  • uploads///Part  Graph
    Company & Industry Overviews

    Celldex Rose on Phase 2 Melanoma Data

    On June 6, 2016, Celldex Therapeutics (CLDX) was one of the top gainers in the small-cap segment of IBB. CLDX stock rose after the company announced its Phase 2 melanoma data.

    By Peter Neil
  • uploads///tablets _
    Earnings Report

    Biogen Stock Trending Higher on Strong Q2 2018 Results

    Today, Biogen (BIIB) announced its earnings results for the second quarter of fiscal 2018. Here’s what you need to know.

    By Sarah Collins
  • uploads///dna _
    Company & Industry Overviews

    PTC Therapeutics to Acquire Agilis Biotherapeutics

    On July 19, PTC Therapeutics (PTCT) agreed to acquire Agilis Biotherapeutics. The acquisition is expected to close during Q3 2018.

    By Daniel Collins
  • uploads///Firefish
    Company & Industry Overviews

    Risdiplam: Could It Be PTC Therapeutics’ Future Growth Driver?

    In June, PTC Therapeutics (PTCT) presented its updated interim clinical data from the Phase 1 FIREFISH trial.

    By Daniel Collins
  • uploads///dna _
    Company & Industry Overviews

    Biogen and Ionis Crash on PTC Therapeutics’ Promising Data

    Yesterday, PTC Therapeutics (PTCT) registered a stock price rise of ~24.6% on the positive data the company presented along with partner Roche (RHHBY) for their SMA (spinal muscular atrophy) drug risdiplam.

    By Sarah Collins
  • uploads///pipeline
    Company & Industry Overviews

    Inside Vertex Pharmaceuticals’ Clinical Pipeline

    In March 2017, Vertex Pharmaceuticals (VRTX) announced promising results from two phase-3 clinical trials, Evolve and Expand.

    By Daniel Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.